Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

This year, JPM 2026 took place again in San Francisco. Let’s look at predictions and trends forecast for 2026, according to ...

Discover how platformed lentiviral manufacturing and ready-to-deploy CAR-T solutions are breaking the critical barriers of ...

Since its spin-out from Abbott in 2013, AbbVie’s pipeline strategy has been built around a dominant immunology franchise anchored by Humira. For much of the past decade, that formula worked very well.

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in December 2025.

Find out about TECregen's, a Basel-based company developing novel biologics designed to rejuvenate the thymus, “thymopoietics.” ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends ...